Semax 10mg

Semax is a synthetic heptapeptide derived from the 4-10 region of the adrenocorticotropic hormone (ACTH), with a terminal Pro-Gly-Pro modification that significantly extends its half-life. It was developed at the Institute of Molecular Biology of the Russian Academy of Sciences in the 1980s and is one of the most widely studied peptide nootropics in the scientific literature.

Molecular structure:

• Met-Glu-His-Phe-Pro-Gly-Pro
• Molecular weight: 813.9 Da
• Average half-life: 60 to 90 minutes (significantly longer than the original ACTH 4-10)
• Valid routes of administration: intranasal and subcutaneous

Unlike full ACTH, Semax lacks activity on the adrenal cortex, which eliminates effects on cortisol and aldosterone, leaving only neuroactive action.

• Increased BDNF and NGF: Semax stimulates the brain's expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), key factors for synaptic plasticity.
• Neurotransmitter Modulation increases dopaminergic and serotonergic tone in specific regions, without causing massive release
• Inhibition of enkephalins and endorphins: protect these endogenous opioids from enzymatic degradation
• Neuroprotective action reduce neuronal damage in models of cerebral ischemia
• Melanocortin receptor activation contributes to the regulation of alertness and attention

• Post-ischemic stroke rehabilitation (clinically approved for use in Russia)
• Memory and learning enhancement in healthy adults
• Attention Deficit Hyperactivity Disorder (ADHD)
• Cognitive fatigue and burnout
• Traumatic Brain Injury Rehabilitation
• Research in mild cognitive impairment and early dementia
• Performance improvement in demanding cognitive tasks

Reconstitution Add 2 ml of bacteriostatic water to the 10 mg vial. Concentration: 5,000 mcg/ml. Each U-100 unit delivers 50 mcg.

Routes of administration

• Intranasal: transfer the reconstituted solution to a sterile dropper. Administer 300 to 600 mcg divided between two nostrils. Preferred route for direct CNS action, superior bioavailability to subcutaneous.
• Subcutaneous 300 to 600 mcg (6 to 12 units U-100), once or twice daily.

Typical layouts:

• Sustained cognition: 300 mcg/day for 2 to 4 weeks, pause for 1 week, repeat
• Intense focus on specific days: 600 mcg in the morning of a demanding day
• Neurological recovery post-ischemia: specific clinical protocols under supervision

Excellent safety profile documented in decades of Russian clinical use. Rare adverse events: local nasal irritation with prolonged intranasal use, mild headache, insomnia if administered late in the day.

Avoid in patients with bipolar disorder or active psychosis due to its dopaminergic action. Do not combine with MAOIs or dopamine reuptake inhibitors without supervision.

• Cognition + emotional stability Semax + Selank (classic Russian combination)
• Neurological Recovery Semax + NAD+ for cerebral mitochondrial support
• Integral burnout: Semax + Selank + DSIP for focus, calm, and sleep

1. Asmarin IP, Nezavibatko VN, Myasoedov NF, et al. A nootropic adrenocorticotropin analog 4-10-Semax: 15 years experience in development and study. J Higher Nervous Activity I P Pavlov. 1997;47(2):420-430.
2. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of adrenocorticotropin (4-10), specifically binds and increases brain-derived neurotrophic factor protein levels in the rat basal forebrain. J Neurochem. 2006;97(Suppl 1):82-86.
3. Shadrina MI, Dolotov OV, Grivennikov IA, et al. Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neurosci Lett. 2001;308(2):115-118.